Newly Approved Obesity Drug Wegovy Holds Promise, But Faces Reimbursement Challenges Clinical trial data suggest that Wegovy works better for treating obesity than other approved drugs. If the clinical evidence holds up in the real world and is durable over time, this may justify payers reimbursing Wegovy as a medically necessary treatment for the eligible obese population.